1025216-57-2

1025216-57-2 structure

Name: Volixibat
Chemical Name: volixibat
CAS Number: 1025216-57-2
Molecular Formula: C₃₈H₅₁N₃O₁₂S₂
Molecular Weight: 805.954
Catalog: Research Areas Metabolic Disease
Create Date: 2018-10-16 22:13:47
Modify Date: 2024-01-09 08:19:52
Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)[1][2].

Name	volixibat
Synonyms	X2JZ0451H8 volixibat 3-O-Benzyl-N-({3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenyl}carbamoyl)-6-O-sulfo-β-D-glucopyranosylamine UNII:X2JZ0451H8 β-D-Glucopyranosylamine, N-[[[3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenyl]amino]carbonyl]-3-O-(phenylmethyl)-, 6-(hydrogen su lfate)

Description	Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)[1][2].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease
In Vivo	Volixibat (SHP626) (5-30 mg/kg; food intake; daily for 24 weeks) improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice[1]. Animal Model: Male Ldlr-/-.Leiden mice (high-fat diet, HFD)[1] Dosage: 5, 15, or 30 mg/kg Administration: Food intake; daily for 24 weeks Result: Significantly increased the total amount of bile acid in feces. Significantly attenuated the HFD-induced increase in hepatocyte hypertrophy, hepatic triglyceride and cholesteryl ester levels, and mesenteric white adipose tissue deposition at the highest dose. Non-alcoholic fatty liver disease activity score (NAS) was significantly lower in volixibat-treated mice than in the HFD controls.
References	[1]. Salic K, et al. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolicaspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019 Jun 24;14(6):e0218459. [2]. Palmer M, et al. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10.

Density	1.4±0.1 g/cm3
Molecular Formula	C₃₈H₅₁N₃O₁₂S₂
Molecular Weight	805.954
Exact Mass	805.291443
LogP	5.35
Index of Refraction	1.651

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

1025216-57-2	1431935-92-0
1506555-31-2	1525718-80-2
1515980-41-2	1779812-55-3
1599244-11-7	1203489-95-5
1502160-25-9	933706-85-5
1861287-33-3	1193708-82-5